1. Mexico Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Genomma Lab Internacional, S.A.B. de C.V.

Genomma Lab Internacional, S.A.B. de C.V.

GNMLF
Genomma Lab Internacional, S.A.B. de C.V.US flagOther OTC
0.84
USD
- -
- -
818.18MMarket Cap
Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
(Other OTC)

Recent

price

0.84

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.95
7.65
9.35
10.83
11.01
10.7
11.54
12.68
11.52
12.55
13.71
15.37
16.93
17.2
19.03
17.94
13.19
Revenue per Share
1.04
1.39
1.43
1.67
1.38
-1.04
-1.71
1.34
1.08
0.74
1.39
1.3
1.4
1.07
1.53
1.65
1.2
Basic EPS, GAAP
0.59
0.01
-0.17
-0.82
0.13
1.03
1.35
1.13
0.05
0.13
1.69
1.25
2.05
2
2.18
2.07
1.37
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.39
0.78
0.61
0.8
0.8
0.4
Dividend per Share
3.94
5.24
6.75
8.33
9.71
8.83
7.57
8.3
7.82
8.56
9.88
11.25
12.37
13.19
13.64
14.49
14.78
Book Value per Share
3.91
5.27
2.61
1.89
2.7
2.15
1.65
1.96
1.74
2.31
3.89
4.87
4.96
4.53
4.98
5.56
6.24
Tangible Book Value per Share
1,053
1,053
1,048
1,049
1,048
1,032
981
952
1,024
1,013
1,012
1,008
993
957
978
978
977
Basic Weighted Avg Shares
6,264
8,056
9,800
11,361
11,541
11,042
11,316
12,078
11,794
12,713
13,870
15,487
16,820
16,467
18,607
17,541
12,884
Sales/Revenue/Turnover
25.78
24.97
25.43
25.8
21.08
-0.62
1.68
20.69
18.54
17.89
21.15
19.35
19.64
19.44
20.99
21.41
21.26
Operating Margin (%)
79
82
66
64
98
118
84
70
81
142
159
170
227
227
360
379
278
Depreciation Expense
1,093
1,461
1,504
1,752
1,445
-1,069
-1,681
1,279
1,109
750
1,404
1,308
1,389
1,026
1,493
1,614
1,169
Net Income, GAAP
30.62
30.35
30.86
30.51
29.45
- -
- -
35.04
37.09
51.49
35.33
41.14
38.84
36.95
27.67
33.68
33.9
Effective Tax Rate (%)
17.45
18.14
15.35
15.43
12.52
-9.68
-14.85
10.59
9.41
5.9
10.12
8.44
8.26
6.23
8.02
9.2
9.08
Profit Margin (%)
3,136
4,443
5,586
6,833
9,542
5,043
2,696
1,536
4,512
4,139
5,424
4,950
1,956
3,997
5,528
5,699
6,009
Working Capital
- -
970
3,052
4,651
6,505
5,829
3,760
1,690
5,197
4,531
4,475
3,856
1,590
4,234
5,113
4,796
4,729
LT Debt
4,112
5,544
7,019
8,835
10,503
9,249
6,793
7,049
6,718
7,249
8,842
10,072
10,152
9,383
10,885
11,118
11,715
Total Equity
30.55
27.04
21.4
17.21
11.36
- -
- -
14.68
12.36
9.08
13.54
11.34
12.42
12.77
17.94
14.57
9.46
Return on Invested Capital (%)
39.84
27.83
18.49
15.27
10.35
- -
- -
11.15
10.93
7.29
10.89
9.29
9.5
8.24
11.04
10.29
7.15
Return on Capital (%)
38.36
30.26
23.89
22.17
15.28
-11.08
-20.33
16.68
13.94
8.99
15.04
12.26
11.76
8.24
11.5
11.74
8.33
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
2,832
3,329
LT Borrowings
- -
4,770
4,729
LT Finance Leases
- -
26
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
978
978
Market Capitalization
20,929
18,646
15,954

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
12,845
13,661
Cash, Cash Equivalents & STI
- -
3,054
2,809
Accounts Receivable, Net
- -
4,496
5,255
Inventories
- -
1,840
1,941
Total Current Liabilities
- -
7,145
7,652
Payables & Accruals
- -
- -
- -
ST Debt
- -
2,832
3,329
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.77%
5.06%
2.14%
Free Cash Flow
131.61%
7.16%
-4.85%
Net Income, GAAP
-5.04%
5.37%
8.1%
Sales/Revenue/Turnover
4.92%
5.09%
-5.73%
Total Cash Common Dividend
- -
- -
0.38%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,197
4,651
5,093
4,666
18,607
2025
4,406
4,676
- -
4,017
17,541
2026
4,191
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.39
- -
0.7
-0.17
1.53
2025
0.51
0.36
- -
0.33
1.65
2026
0.51
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
- -
0.21
0.19
0.8
2025
0.2
- -
- -
0.2
0.8
2026
0.2
- -
- -
- -
- -
Similar Companies
Hempfusion Wellness Inc. (CBDHF)
Bhang Inc. (BHNG.CN)
Curative Biosciences, Inc. (CBDX)
LFTD Partners Inc. (LIFD)
Emplicure AB (publ) (EMPLI.ST)
Ozon Pharmaceuticals (OZPH.ME)
Business
Genomma Lab Internacional, S.A.B. de C.V. develops, manufactures, markets and distributes over-the-counter (OTC) medicines, generic drugs, personal care products, isotonic beverages and infant nutrition products across Mexico, the United States and Latin America; core offerings include gastroanalgesics and analgesics such as Tafirol and IBU 400, cough and cold remedies, dermacare OTCs including Asepsia and Cicatrocure, skincare and hair care lines featuring Tionacho and Bernard, razors, Suerox isotonic beverages alongside Suero Repone and Suero Oral, and infant nutrition brands like NovoMil and Novalac; products reach consumers through pharmacies, supermarkets, department stores, grocery stores, wholesalers and over 600,000 traditional channel points of sale. Founded in 1996 and headquartered in Mexico City, the company operates in 18 countries including Argentina, Brazil, Chile, Colombia, Peru and others, with sales split approximately 48% Mexico, 42% Latin America and 10% United States, and employs 1,665 people while generating MXN 18,607 million in 2024 sales. Recent developments encompass the July 2024 bolt-on acquisitions of Suero Repone, Suero Oral, IBU 400 and Treg brands for US$25.6 million to bolster isotonic, analgesic and gastro categories; divestiture of its Marzam stake in May 2024; issuance of LAB 25 and LAB 25-2 unsecured bonds for MXN 1.2 billion in June 2025 and prepayment of the LAB 23 bond; relaunch of Asepsia skincare and plans for NovoMil infant nutrition in Brazil and Argentina; strategic agreement with Procaps Group in 2023 for softgel manufacturing; and ongoing expansion targeting over 800,000 traditional points of sale.

Company News

APIChatGPT

  • seekingalpha.com

    Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q1 2026 Earnings Call Transcript

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the First Quarter 2026

  • prnewswire.com

    Genomma Lab Internacional S.A.B. de C.V. First Quarter 2026 Earnings Results Conference Call

  • seekingalpha.com

    Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q4 2025 Earnings Call Transcript

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the Fourth Quarter and Full Year 2025

  • prnewswire.com

    Genomma Lab Internacional S.A.B. de C.V. Fourth Quarter 2025 Earnings Results Conference Call

  • prnewswire.com

    GENOMMA LAB INTERNACIONAL ANNOUNCES FOURTEENTH DIVIDEND PAYMENT

  • prnewswire.com

    GENOMMA LAB INTERNACIONAL ANNOUNCES FOURTEENTH DIVIDEND PAYMENT

  • seekingalpha.com

    Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q3 2025 Earnings Call Transcript

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the Third Quarter 2025

  • prnewswire.com

    Genomma Lab Internacional S.A.B. de C.V. Third Quarter 2025 Earnings Results Conference Call

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the Second Quarter 2025

  • prnewswire.com

    GENOMMA LAB INTERNACIONAL ANNOUNCES TWELFTH DIVIDEND PAYMENT

  • prnewswire.com

    GENOMMA LAB INTERNATIONAL INFORMS TOTAL PREPAYMENT OF "LAB 23" UNSECURED LOCAL BOND (CEBUR)

  • prnewswire.com

    Genomma Lab successfully issued the LAB 25 and LAB 25-2 unsecured bonds (Cebures) for a total amount of $1.2 billion pesos, which will be used to prepay liabilities, including the full early amortization of the LAB 23 bond

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the First Quarter 2025

  • prnewswire.com

    Genomma Lab Internacional S.A.B. de C.V. First Quarter 2025 Earnings Results Conference Call

  • prnewswire.com

    GENOMMA LAB INTERNACIONAL ANNOUNCES ELEVENTH DIVIDEND PAYMENT

  • prnewswire.com

    Genomma Lab Internacional Announces Results for the Fourth Quarter and Full Year 2024

  • prnewswire.com

    Genomma Lab Internacional S.A.B. de C.V. Fourth Quarter 2024 Earnings Results Conference Call